The most serious problem of nucleoside/nucleotide analogue therapy for hepatitis B virus (HBV) infection is the emergence of drug-resistant mutant virus. Here, we describe a patient with chronic hepatitis B infection with a complex drug-resistant mutant virus during sequential therapy with lamivudine (3TC), entecavir (ETV) and adefovir dipivoxil (ADV). The patient was a 52-year-old male with positive hepatitis B e antigen and high HBV DNA (>7.6 log 10 copies/ ml). Initial 3TC monotherapy offered little benefit and 3TC resistance was established by the virus with rtA181T and not rtM204V/I. HBV DNA was reduced slightly by replacement with ETV monotherapy and was followed by virological breakthrough. At that time, rtA181T was undetectable and the virus with rtM204V and rtL180M became predominant. ETV resistance was established by an additional rtS202G mutation. Efficacy of subsequent combination therapy with ADV and 3TC was limited because of reappearance of the virus with rtA181T, which might confer cross-resistance to 3TC and ADV. Final combination therapy with ETV and ADV reduced HBV DNA to 3.7 log 10 copies/ml for 5 months, which was the most effective therapy for this patient. Thus, two kinds of mutant viruses (rtM204V-related and rtA181T-related) appeared alternately in this patient. Combination therapy with ETV and ADV might have been effective because these drugs share therapeutic roles, that is, ETV affects the rtA181T-related virus and ADV affects the rtM204V-related virus. This is the first report suggesting clinical significance of combination therapy with ETV and ADV for controlling replication of the complex drugresistant mutant HBV.
Nucleoside/nucleotide analogues have a better therapeutic effect on chronic hepatitis B virus (HBV) infection than previously used drugs. They strongly suppress HBV replication and retard disease progression [1, 2] ; however, the most serious problem associated with nucleoside/nucleotide analogues is the emergence of drug-resistant viruses through long-term administration. Drug-resistant viruses for nucleoside/nucleotide analogues occur as a result of amino acid substitutions within the reverse transcriptase (RT) domain of the HBV polymerase gene. Lamivudine (3TC) resistance is primarily caused by mutations rtM204V/I and rtL180M, the latter of which is a compensatory substitution [3, 4] . Adefovir dipivoxil (ADV) resistance is associated with the mutations rtA181V/T and/ or rtN236T [5] . Entecavir (ETV) resistance is established by substitution(s) at rt184, rt202 and/or rt250 in addition to 3TC-resistant substitutions, rtM204V and rtL180M [6] .
Recently, the substitution at rt181 has been reported to confer cross-resistance not only to ADV, but also to other nucleoside/nucleotide analogues [7, 8] . Some investigators have suggested that 3TC resistance can occur not only with rtM204V/I, but also with rtA181T [9, 10] . A more recent report has shown that rtA181V/T is involved in resistance to multiple drugs, including 3TC, ADV and tenofovir disoproxil fumarate, although the degree of drug resistance varies considerably among HBV strains in vitro [8] .
In this report, we describe a chronic HBV patient who has a complex drug-resistant mutant virus that was identified during sequential therapy with three nucleoside/nucleotide analogues. In this patient, two kinds of mutant viral strains based on the rtM204V and 
Case report

Patient clinical course
The patient was a 52-year-old male who first visited Osaka University Hospital (Osaka, Japan) in September 2004. He had been diagnosed as a chronic HBV carrier 5 years earlier. He was a chronic drinker, with alcohol consumption of approximately 65 g/day. He had also suffered from type-2 diabetes mellitus for >10 years and had undergone insulin therapy for 10 months.
The laboratory data at his first visit were alanine aminotransferase (ALT) 68 IU/l (normal level ≤40 IU/l), aspartate aminotransferase (AST) 75 IU/l (normal level ≤40 IU/l), γ-glutamyl transpeptidase (GGT) 189 IU/l (normal level <50 IU/l), fasting plasma glucose (FPG) 239 mg/dl (normal level ≤110 mg/dl), glycated haemoglobin (HbA1c), 10.3% (normal range 4.3-5.8%) and HBV DNA>7.6 log 10 copies/ml. Hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) were positive, whereas antibodies against HBsAg (antiHBs), HBeAg (anti-HBe), hepatitis C virus and HIV were negative. Liver histology showed mild piecemeal necrosis, mild lobular inflammation and mild portal fibrosis; however, steatosis was found in only <5% of the hepatocytes. 3TC (100 mg/day) therapy was commenced in October 2004. Sequencing analysis before therapy revealed no drug-resistance-associated mutations. After starting 3TC therapy, HBV DNA decreased to 6.5 log 10 copies/ml in February 2006 and increased again to >7.6 log 10 copies/ml in April 2006. ALT levels were almost abnormal and on one occasion flared up to 472 IU/l in December 2005 despite cessation of drinking. rtM204V/I was not detected by repeated PCR-enzyme-linked minisequence assay [11] , but rtA181T was found by sequencing analysis in October 2006. At this point, 3TC was switched to ETV monotherapy (0.5 mg/ day). The laboratory data at the beginning of ETV administration were ALT 64 IU/l, AST 78 IU/l, GGT 268 IU/l and HBV DNA>7.6 log 10 copies/ml. Diabetes mellitus was improved (FPG 123 mg/dl and HbA1c 6.9%) because of a strict diet. During ETV therapy, HBV DNA decreased to 5.6 log 10 copies/ml in February 2007, but virological breakthrough was observed in August 2007 (HBV DNA 6.7 log 10 copies/ml). As for drug-resistance-associated mutations, rtM204V and rtL180M were detected in September 2007, and rtS202G was detected in January 2008 despite an increasing dose of ETV (1 mg/day). ETV administration was stopped in March 2008 and replaced by combination therapy of 3TC (100 mg/day) with ADV (10 mg/day). The laboratory data at that time were ALT 29 IU/l, AST 49 IU/l, GGT 161 IU/l and HBV DNA 7.0 log 10 copies/ml. The combination therapy led to a slight decrease in HBV DNA to 5.6 log 10 copies/ml in June 2008. In September 2008, rtA181T was detected again, whereas rtL180M, rtS202G and rtM204V were not detected. From October 2008, a combination therapy with ADV (10 mg/day) and ETV (0.5 mg/day) was carried out. HBV DNA decreased from 5.8 to 3.7 log 10 copies/ml for 5 months. In this patient, ALT fluctuated within the normal to slightly abnormal range (≤60 IU/l) during ETV monotherapy and subsequent combination therapy. Improvement of liver function was observed despite poor control of HBV replication and appeared to be greatly attributed to recovery from alcoholic and diabetes mellitusrelated liver diseases. Throughout the follow-up period, no side effects from the nucleoside/nucleotide analogues were observed. The clinical course of the patient is summarized in Figure 1 .
Serological and virological assays for HBV
HBsAg, anti-HBs, HBeAg and anti-HBe were determined by chemiluminescent immunoassays. HBV DNA was quantified by a PCR-based method (Amplicor HBV monitor; Roche Diagnostics, Basel, Switzerland). The 3TC-resistant rtM204V/I substitution was examined by PCR-enzyme-linked minisequence assay [11] . Nucleotide sequences of the entire RT region were determined by PCR direct sequencing. The primers BF5 (5′-AAGAGACAGTC ATCCTCAGG-3′, nucleotides 3183-3202) and BR8 (5′-TTGCGTCAGCAAACACTTGG-3′, nucleotides 1195-1176) were used for the amplification. The sequencing analyses were done using sera collected in 
Results of sequencing analyses
Sequencing data showed that the patient was infected with HBV genotype C according to phylogenetic tree analysis (data not shown). The results of serial sequencing analyses from P1 to P5 are shown in Figure 2 . The virus with rtA181T and rtF221Y was detected at P2. By contrast, the virus with rtL180M, rtM204V, rtL229V and rtL269I became predominant at P3. At P4, rtS202G was added, although it occurred incompletely; however, the dominant virus at P5 possessed rtA181T and rtF221Y and was identical to that at P2.
We also compared HBV DNA sequences around rt180 and rt181 obtained at P1-P5 (Figure 3) . At P2 and P5, two types of mutations were identified: one was an A670 mutation causing rtA181T and an in-frame stop codon formation at codon 172 of the S gene, and the other was a C669/A670 double mutation, which resulted in rtA181 but avoided the stop codon formation in the S gene. At P3 and P4, the A667 mutation, which led to rtL180M, was detected.
Discussion
In this paper, we have described a chronic hepatitis B patient with a complex drug-resistant mutant virus. In this patient, initial 3TC monotherapy offered little benefit and virological breakthrough was observed after administration. 3TC resistance was not caused by rtM204V/I but by rtA181T. After 3TC was replaced by ETV, HBV DNA decreased to 5.6 log 10 copies/ml, followed by virological breakthrough for a short period of time. At that time, rtA181T was not detected, and the virus with rtM204V and rtL180M was predominant. This indicates that the virus with rtM204V and rtL180M might have already coexisted as a minor population before ETV therapy, and that the virus with rtA181T might have been reduced because of its susceptibility to ETV. Indeed, the virus with rtA181V/T has been reported to be sensitive to ETV in vitro [8] . The ETV resistance-specific rtS202G was not yet seen at the time of virological breakthrough. It was observed a short time later, resulting in the establishment of ETV resistance, although the reasons for virological breakthrough prior to the detection of the ETV-resistant HBV strain remains to be understood.
Subsequently, combination therapy with ADV and 3TC was done because ADV has been reported to have an effect on ETV resistance [12, 13] ; however, its efficacy was limited and the virus with rtA181T reappeared. The virus with rtM204V, rtL180M and rtS202G became undetectable. This might be because the virus with rtM204V, rtL180M and rtS202G was susceptible P3 ----------------------------------------------------------------------------------------------------P4 ----------------------------------------------------------------------------------------------------P5 ----------------------------------------------------------------------------------------------------P1 LLVGSSGLPRYVARLSSTSRNINYQHGTMQDLHDSCSRNLYVSLLLLYKTFGRKLHLYSHPIILGFRKIPMGVGLSPFLLAQFTSAICSVVRRAFPHCLA  P2 --------------------------------------------------------------------------------T-------------------P3 -------------------------------------------------------------------------------M--------------------P4 -------------------------------------------------------------------------------M------------------ to ADV, whereas the virus with rtA181T revealed resistance to 3TC and possibly ADV. Final combination therapy with ETV and ADV resulted in a decrease in HBV DNA to 3.7 log 10 copies/ml for 5 months, which was the most effective therapeutic regimen for this patient. Thus, two kinds of drug-resistant viral strains, the rtA181T-related strain and the rtM204V-related strain, appeared alternately in this patient. It is noteworthy that combination therapy with ETV and ADV was effective against such a complex mutant HBV. This might be because of the sharing of therapeutic roles of these drugs: ETV for the rtA181T-related strain and ADV for the rtM204V-related strain. rtA181T, which is generally caused by the A670 mutation, results in the in-frame stop codon formation at codon 172 of the S gene. In this patient, the virus with the C669/A670 double mutation, which could produce the surface protein, coexisted with the virus with the A670 mutation alone. A similar virus with the T669/A670 double mutation, which compensates for the defect of surface protein production, has also been reported [7, 14] .
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In summary, we have reported on a complex drugresistant mutant HBV related to both rtA181T and rtM204V substitutions in a patient with chronic HBV, who received sequential therapy of nucleoside/nucleotide analogues. We also showed for the first time that combination therapy with ETV and ADV might be of clinical significance for controlling replication of complex mutant HBV.
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